Arvinas to Present at Upcoming Conferences

NEW HAVEN, Conn., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will participate in two upcoming conferences:

• Society for Neuroscience (SFN) Annual Meeting: Saturday, November 12, 4:00-5:00 p.m. PT. Angela Cacace, Ph.D., Senior Vice President of Neuroscience and Platform Biology, will deliver a poster presentation titled, “Orally Administered PROTAC® Molecules Selectively Clear Pathologic Neurodegenerative Proteins in CNS & Muscle.”
• Stifel Healthcare Conference: Tuesday, November 15 at 11:30 a.m. ET. Ron Peck, M.D., Chief Medical Officer, and Randy Teel, Ph.D., Senior Vice President, Corporate and Business Development, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events & Presentations section of the Investors & Media section of the Company’s website.

About ArvinasArvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs: bavdegalutamide (ARV-110) and ARV-766 for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com.

Contacts

Investors:Jeff Boyle+1 (347) 247-5089[email protected]

Media:Kirsten Owens+1 (203) 584-0307[email protected] 

You May Also Be Interested In

• Stingray Provides Update on Management Cease Trade Order
• Lexitas Pharma Services and Ocusun Enroll First Patient in a Pilot Study for an Upcoming Phase III Clinical Trial Evaluating Investigational Eye Drop for Age-Related Cataract
• Corgi SK Hynix 2x Daily ETF (SK) Is Now Trading: The Lowest-Cost 2x Long SK Hynix ETF at a 0.50% Expense Ratio